{"title":"治疗无效的新生血管性年龄相关性黄斑变性的玻璃体内法尼单抗：英国一家中心在负荷剂量后延长 12 周的实际效果。","authors":"Ashish Patwardhan, Nadir Ali, Stacey Law","doi":"10.1038/s41433-024-03487-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To assess the visual outcome of extension to 12-weekly intervals (Q12W) following 4 loading doses of intravitreal Faricimab injections as described in the TENAYA and LUCERENE trials for the management of treatment-naïve neovascular Age-related Macular Degeneration (nAMD).</p><p><strong>Methods: </strong>A retrospective analysis was carried out on all treatment-naïve nAMD patients who started Faricimab intravitreal injections in the period between 1<sup>st</sup> September 2022 and 31<sup>st</sup> January 2023. The data collection included best corrected visual acuity (BCVA) at baseline, 12 weeks, 24 weeks and 52 weeks; Central Subfield Thickness (CST) at baseline, 24 weeks and 52 weeks; Number of injections at 52 weeks; treatment intervals at 52 weeks. Descriptive and correlational analysis, independent and Paired-sample T-tests were used to analyse the data.</p>","PeriodicalId":12125,"journal":{"name":"Eye","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Intravitreal Faricimab in treatment-naïve neovascular age-related macular degeneration: real-world outcome of 12-week extension after the loading dose from a UK centre.\",\"authors\":\"Ashish Patwardhan, Nadir Ali, Stacey Law\",\"doi\":\"10.1038/s41433-024-03487-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To assess the visual outcome of extension to 12-weekly intervals (Q12W) following 4 loading doses of intravitreal Faricimab injections as described in the TENAYA and LUCERENE trials for the management of treatment-naïve neovascular Age-related Macular Degeneration (nAMD).</p><p><strong>Methods: </strong>A retrospective analysis was carried out on all treatment-naïve nAMD patients who started Faricimab intravitreal injections in the period between 1<sup>st</sup> September 2022 and 31<sup>st</sup> January 2023. The data collection included best corrected visual acuity (BCVA) at baseline, 12 weeks, 24 weeks and 52 weeks; Central Subfield Thickness (CST) at baseline, 24 weeks and 52 weeks; Number of injections at 52 weeks; treatment intervals at 52 weeks. Descriptive and correlational analysis, independent and Paired-sample T-tests were used to analyse the data.</p>\",\"PeriodicalId\":12125,\"journal\":{\"name\":\"Eye\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-11-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Eye\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41433-024-03487-2\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eye","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41433-024-03487-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的评估TENAYA和LUCERENE试验中描述的治疗无效新生血管性年龄相关性黄斑变性（nAMD）的法利单抗玻璃体内注射4次负荷剂量后延长至12周间隔（Q12W）的视觉效果：对2022年9月1日至2023年1月31日期间开始接受法利西单抗玻璃体内注射的所有治疗无效的nAMD患者进行回顾性分析。收集的数据包括基线、12周、24周和52周的最佳矫正视力（BCVA）；基线、24周和52周的中央视野下厚度（CST）；52周的注射次数；52周的治疗间隔。数据分析采用了描述性和相关性分析、独立和配对样本 T 检验。
Intravitreal Faricimab in treatment-naïve neovascular age-related macular degeneration: real-world outcome of 12-week extension after the loading dose from a UK centre.
Objectives: To assess the visual outcome of extension to 12-weekly intervals (Q12W) following 4 loading doses of intravitreal Faricimab injections as described in the TENAYA and LUCERENE trials for the management of treatment-naïve neovascular Age-related Macular Degeneration (nAMD).
Methods: A retrospective analysis was carried out on all treatment-naïve nAMD patients who started Faricimab intravitreal injections in the period between 1st September 2022 and 31st January 2023. The data collection included best corrected visual acuity (BCVA) at baseline, 12 weeks, 24 weeks and 52 weeks; Central Subfield Thickness (CST) at baseline, 24 weeks and 52 weeks; Number of injections at 52 weeks; treatment intervals at 52 weeks. Descriptive and correlational analysis, independent and Paired-sample T-tests were used to analyse the data.
期刊介绍：
Eye seeks to provide the international practising ophthalmologist with high quality articles, of academic rigour, on the latest global clinical and laboratory based research. Its core aim is to advance the science and practice of ophthalmology with the latest clinical- and scientific-based research. Whilst principally aimed at the practising clinician, the journal contains material of interest to a wider readership including optometrists, orthoptists, other health care professionals and research workers in all aspects of the field of visual science worldwide. Eye is the official journal of The Royal College of Ophthalmologists.
Eye encourages the submission of original articles covering all aspects of ophthalmology including: external eye disease; oculo-plastic surgery; orbital and lacrimal disease; ocular surface and corneal disorders; paediatric ophthalmology and strabismus; glaucoma; medical and surgical retina; neuro-ophthalmology; cataract and refractive surgery; ocular oncology; ophthalmic pathology; ophthalmic genetics.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
